A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEXAfter Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Anti-TA-MUC1 monoclonal antibody (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Glycotope
- 24 Oct 2017 This study has been completed in Spain as per Eudra.
- 10 Sep 2017 This study has been discontinued in Poland (End date: 2017-08-15) as per Eudra.
- 15 Aug 2017 This study has been discontinued in Hungary as per Eudra.